Arbutiol, polyhydroxy derivative thereof, composition of arbutiol and application of arbutiol

The conversion of urfolol into a polyhydroxy derivative through microbial transformation technology solves the problem of limited biological activity, realizes effective treatment for neurological diseases and anti-tumors, and significantly improves biological activity and drug efficacy.

CN118909020AActive Publication Date: 2024-11-08NANTONG UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410998337.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-24
Publication Date
2024-11-08
Estimated Expiration
2044-07-24

AI Technical Summary

Technical Problem

The biological activity of urfolol in anti-tumor and other diseases is limited by its poor solubility, low bioavailability and difficult structural modification, especially in the treatment of neurological diseases.

Method used

Through microbial transformation technology, urfolol is converted into polyhydroxy derivatives using Elegant Radiomucor Actinomucor elegans CGMCC 3.3393, and compounds with stronger biological activity are prepared by fermentation, extraction, chromatography purification and other steps to treat neurological diseases. and anti-tumor.

Benefits of technology

The obtained polyhydroxy aurfolol derivatives showed significant nerve cell damage repair, anti-neurotic inflammation and anti-tumor activity, which can improve the learning and memory ability of mice, and showed good efficacy in in vivo and in vitro tests, with Wide therapeutic potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909020A_ABST
    Figure CN118909020A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and discloses arbutin, a polyhydroxy derivative thereof, a composition of the arbutin and application of the arbutin. According to the invention, a microbial transformation method is utilized to successfully carry out structural modification on the arbutin, three novel polyhydroxy substituted arbutin derivatives are obtained, and an in-vitro nerve cell inflammation test and a nerve cell oxidative damage protection test prove that the arbutin derivatives have a good application prospect. The compounds have good anti-neuroinflammation and nerve cell injury protection activity. Meanwhile, in-vivo Alzheimer's disease mouse model experiments prove that the compounds can significantly improve the learning and memory ability of AD mice, and can be used as active ingredients of drugs for treating nervous system diseases. In-vitro anti-tumor cell tests prove that the compounds as shown in the formulas I-III have remarkable anti-tumor activity, can be used as active ingredients of anti-tumor drugs and have wide application.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines and relates to ursodiol, its polyhydroxy derivatives and a composition and use thereof. Background Art

[0002] Ursolic acid, also known as ursolic acid, is a natural ursane-type pentacyclic triterpenoid compound widely distributed in olives, including olive leaves, bark, fruit and extra virgin olive oil. The content of ursolic acid is one of the important indicators for people to evaluate the quality of olive oil. It can also be isolated from different parts of plants such as bayberry, camellia oil, oleander, lavender, apple, etc. Preliminary studies have shown that ursolic acid has multiple pharmacological activities, including anti-inflammatory, cardiotonic, anti-arrhythmic and anti-tumor, and can promote the healing of skin wounds. At present, there are no reports on the application of ursolic acid in the treatment of neurological diseases.

[0003] In addition, due to the poor solubility, low bioavailability, and the limited number of hydrogen bond donors in the mother nucleus and the limited number of rotatable bonds in the rigid skeleton, ursolic alcohol has limited biological activity in anti-tumor and other diseases. In order to improve these properties of ursolic alcohol, functional groups need to be introduced on the saturated CH bonds, which is difficult to achieve with conventional chemical modification. Microbial transformation is a simple and effective structure modification technology for natural compounds, which can introduce functional groups in a regioselective and stereoselective manner, and has the advantages of high efficiency, economy, and environmental protection. On the one hand, the transformation products obtained by microbial transformation can obtain derivatives with stronger biological activity for direct drug development. On the other hand, the newly introduced chemically active groups on the mother nucleus after microbial transformation increase the sites for chemical modification and transformation, thereby solving the problem of few reaction sites for the organic chemical preparation of derivatives of triterpenoid compounds. However, compared with chemical synthesis, the method of microbial transformation has great randomness, and the results of the transformation cannot be predicted like chemical synthesis, nor can it be designed purposefully. At the same time, even if similar substrates are catalytically transformed by the same strain or different strains, the products obtained will have very significant differences. And the transformation products that can be obtained after the same substrate is transformed by different strains may also have very significant differences. Therefore, it is crucial to select the appropriate strain when using microbial transformation methods to modify the structure of compounds. Summary of the invention

[0004] In view of this, the object of the present invention is to provide ursodiol, its polyhydroxy derivatives and compositions and uses thereof.

[0005] In the first aspect of the present invention, there is provided an ursodiol polyhydroxy derivative represented by any one of the following structural formulas:

[0006]

[0007] The second aspect of the present invention provides a method for preparing the above-mentioned ursodiol polyhydroxy derivatives, comprising the following steps:

[0008] 1) fermenting and culturing a microorganism, adding ursolic alcohol, performing transformation culture, removing mycelium, and obtaining a fermentation liquid, wherein the microorganism is Actinomucor elegans CGMCC 3.3393;

[0009] 2) extracting the fermentation broth with an organic solvent, and evaporating the extract to obtain a crude conversion extract;

[0010] 3) purifying the crude conversion extract by reverse phase silica gel column chromatography, wherein the reverse phase silica gel column chromatography purification adopts a methanol-water two-phase system gradient elution, and collecting and merging the components;

[0011] 4) Purifying the combined components obtained in step 3) by reverse phase high performance liquid chromatography to obtain the ursodiol polyhydroxy derivative.

[0012] The third aspect of the present invention provides a use of ursolic acid or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating a nervous system disease. The structural formula of the ursolic acid is as follows:

[0013]

[0014] The fourth aspect of the present invention provides the use of the above-mentioned ursodiol polyhydroxy derivatives or pharmaceutically acceptable salts thereof in the preparation of drugs for treating nervous system diseases.

[0015] Furthermore, the drug for treating nervous system diseases is a drug for repairing nerve oxidative stress damage.

[0016] Furthermore, the drug for treating nervous system diseases is an anti-neuroinflammatory drug.

[0017] Furthermore, the drug for treating a nervous system disease is a drug for treating Alzheimer's disease.

[0018] The fifth aspect of the present invention provides the use of the above-mentioned ursool polyhydroxy derivatives in the preparation of anti-tumor drugs, wherein the tumor includes one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.

[0019] Furthermore, the present invention provides the use of the above-mentioned ursool polyhydroxy derivatives in the preparation of drugs for killing leukemia drug-resistant cells.

[0020] The sixth aspect of the present invention provides a pharmaceutical composition comprising the above-mentioned ursodiol polyhydroxy derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0021] Furthermore, the pharmaceutically acceptable excipient is one or more of a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, a surfactant, an adsorption carrier and a lubricant.

[0022] Compared with the prior art, the present invention successfully modified the structure of ursolic acid by using microbial transformation technology, and obtained a new type of polyhydroxy substituted ursolic acid derivatives. The in vitro neuronal cell oxidative stress damage protection test and the neuromicroglial cell inflammation test confirmed that these compounds have good neuronal cell damage repair and anti-neuroinflammatory activity. In vivo AD mouse model experiments confirmed that the compounds can significantly improve the learning and memory ability of mice and can be used as active ingredients for drugs for treating nervous system diseases. In vitro anti-tumor cell tests confirmed that compounds of formula I-III have significant anti-tumor activity and can be used as active ingredients for anti-tumor drugs, with a wide range of uses. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 It is the time that the mouse stays in the platform quadrant in Example 4. DETAILED DESCRIPTION

[0024] To further illustrate the present invention, the preparation method of the polyhydroxy ursodiol derivatives provided by the present invention and the application thereof in the preparation of anti-tumor drugs are described in detail below in conjunction with examples.

[0025] Example 1. Preparation of compounds of formula I to formula III

[0026] The present invention adopts a microbial transformation method, uses ursolic acid as a raw material, and prepares the compound of the present invention through fermentation, extraction, separation and other steps. Actinomucor elegans CGMCC 3.3393 was purchased from the Microbial Culture Collection Management Center of the Chinese Academy of Sciences (CGMCC), and potato culture medium was selected and stored in a 4°C refrigerator on a solid slant culture medium.

[0027] Taking Actinomucor elegans CGMCC 3.3393 as an example, the process for preparing compounds of formula I to formula III is as follows:

[0028] 1) Fermentation, transformation and extraction

[0029] Actinomucor elegans CGMCC 3.3393 was inoculated into a 250 mL conical flask (containing 100 mL potato liquid culture medium) as seed liquid. After shaking culture on a shaker at 160 rpm and 26 ° C for 12 hours, when the mycelium growth is in a vigorous stage, 1 mL of seed liquid was taken with a sterile pipette and added to 20 1000 mL shake flasks (containing 400 mL potato liquid culture medium). After shaking culture for 24 hours, 25 mg of ursolic acid (0.25 mL, 100 mg / mL ethanol solution) was added to each shake flask, and a total of 500 mg of substrate was used. The transformation was continued for 7 days under the same conditions, the fermentation broth was filtered, the mycelium was filtered out, and the filtrate was extracted 3 times with an equal volume of ethyl acetate. The extract was concentrated to dryness under reduced pressure to obtain a crude extract of about 1.05 g of the transformant.

[0030] 2) ODS-C18 column chromatography separation

[0031] The crude extract was separated by ODS-C18 column chromatography, with methanol:water gradient elution (20:80, 30:70, 60:40, 80:20, 100:0). The fractions were collected and combined after HPLC analysis to obtain combined components Fr.1-Fr.5.

[0032] 3) Reverse-phase HPLC purification

[0033] Component Fr.2 was purified by reverse phase high performance liquid chromatography. The preparation conditions were semi-preparative chromatography column YMC ODS A-5μm, 12.0×250mm, acetonitrile-water (40:60, V / V), flow rate 3.0mL / min, detection wavelength 203nm. Conversion products with structural formulas of Formula I, Formula II and Formula III were obtained. The mass spectra and spectroscopic data of compounds of Formula I to Formula III are shown below.

[0034] Compound Ⅰ: 7β-hydroxy-21-carbonylarbutol; optical rotation High resolution mass spectrum m / z 495.3442[M+Na] + (ca l cd.C 30 H 48 O4Na, 495.3450); the H NMR and C NMR data are shown in Table 1.

[0035] Compound II: 7β,21β,23-trihydroxyarbutol; optical rotation High resolution mass spectrum m / z 513.3560 [M+Na] + (ca l cd.C 30 H 50 O5Na, 513.3556); the H NMR and C NMR data are shown in Table 1.

[0036] Compound III: 7β,21β-dihydroxy-28-acetyl arbutol; optical rotation High resolution mass spectrum m / z539.3719, [M+Na] + (ca l cd.C 32 H 52 O5Na, 539.3712); the H NMR and C NMR data are shown in Table 1.

[0037] Table 1. H NMR and C NMR data of compounds of formula I to formula III

[0038]

[0039]

[0040]

[0041] The above results show that the structures of the obtained compounds of formula I to formula III are correct.

[0042] Example 2. Repair and protection activity of compounds of formula I to formula III on nerve cells damaged by hydrogen peroxide

[0043] 1) Experimental Materials

[0044] CO2 incubator (Jouan IGO150); microplate reader (Bio-TEK ELx800); fluorescence inverted microscope (Olympus IX51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotechnology Research Institute), DMEM high glucose medium (Gibco l BRL), fetal bovine serum, dimethyl sulfoxide (DMSO), trypsin (Shanghai Bioengineering Co., Ltd.), 30% hydrogen peroxide (H2O2) (Tianjin Ruijinte Chemical Co., Ltd.), PC-12 cells (Institute of Oncology, Chinese Academy of Medical Sciences).

[0045] 2) Experimental methods

[0046] The MTT method was used to determine the effects of each test compound on the activity of H2O2-damaged PC-12 cells: after trypsin digestion, the cells were counted and the cell density of the cell suspension was adjusted to 5×10 4 / mL, add 200μL to each well of a 96-well culture plate, and culture in a 5% CO2, 37℃ constant temperature CO2 incubator for 12h. After the cells adhere to the wall, they are divided into groups for treatment: control group, model group (H2O2700μmol / L damage for 4h), model + test compound (1, 5, 10μM) group. The final volume of each well is 200μL, and 3 parallels are set for each concentration. After 24h of drug treatment, add 10μL of MTT solution (5mg / mL, i.e. 0.5% MTT) to each well and continue to culture for 4h. Measure the absorbance of each well at 490nm with an enzyme reader, and calculate the cell survival rate: cell survival rate = OD value of the drug group / OD value of the control group.

[0047] 3) Experimental results

[0048] According to the test results of the MTT method, the effects of ursolic acid and compounds Ⅰ–Ⅲ of the present invention on the survival rate of PC-12 cells damaged by H2O2 were calculated and the results are shown in Table 2.

[0049] Table 2. Effects of the test samples on the survival rate of PC-12 cells damaged by H2O2

[0050]

[0051] (Compared with the model group, * P<0.05, ** P<0.01, *** P<0.001)

[0052] Compared with the control group, the cell survival rate of the H2O2-treated group was significantly reduced, indicating that the cell model was successfully established. Compared with the H2O2-treated group, donepezil hydrochloride (positive drug) and compounds I-III can significantly increase the cell survival rate, indicating that compounds I-III of the present invention have significant effects on repairing nerve cell damage, and show a good dose-dependent relationship within a certain dose range, and can be used as active ingredients of drugs for treating nerve oxidative damage.

[0053] Example 3. Anti-neuroinflammatory activity of compounds of formula I to formula III of the present invention

[0054] 1) Experimental Materials

[0055] Instruments and reagents: CO2 incubator (Jouan I GO150); microplate reader (Bio-TEK ELx800); fluorescence inverted microscope (Olympus IX51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotechnology Research Institute), RPMI 1640 culture medium (Gibco BRL), microglial cells BV-2, RNase A, fetal bovine serum, dimethyl sulfoxide (DMSO), and trypsin (Shanghai Bioengineering Co., Ltd.).

[0056] Test samples: arbutin and compounds I-III synthesized in Example 1, with a purity of more than 95%; at the same time, L-monomethylarginine (L-NMMA) was selected as a positive control drug, and each compound was dissolved in DMSO and then diluted.

[0057] 2) Experimental methods

[0058] The MTT method was used to determine the effect of each test compound on the viability of the microglial BV-2 cells: BV-2 cells in the logarithmic growth phase were cultured in DMEM containing 10% calf serum and 1% penicillin-streptomycin double antibody solution, and the cell concentration was adjusted to 5×10 4 / mL, inoculated in 96-well culture plates, drug treatment group and cell control group added 100μL cell suspension per well, each group set up 3 replicates, blank control group only added DMEM complete culture medium, 100μL per well, set up 3 replicates. After culturing the 96-well culture plate in a 37°C, 5% CO2 incubator for 24h, different concentrations of the test samples were added to make the final concentration 0.1-100μM, and continued to culture for 72h. According to the MTT method, the absorbance (A) value at 490nm was measured in an enzyme reader, and the inhibition rate was calculated [inhibition rate = (1-experimental group A value / control group A value) × 100%].

[0059] The Griess method was used to determine the effects of each test compound on LPS-induced NO release in BV-2 cells: the cell concentration was adjusted to 2×10 5 The cells were inoculated into 96-well culture plates with 1 mL of cell suspension per well. Three replicate wells were set up for each group. The blank control group was added with only DMEM complete culture medium, with three replicate wells. After the 96-well culture plates were placed in a 37°C, 5% CO2 incubator for 24 hours, different concentrations of the test samples were added to make the final concentration 0.1-100 μM. After continuing to culture for 12 hours, the supernatant was taken and the NO level in the culture medium was determined according to the instructions of the kit. The data were analyzed and processed using SPSS Statistics 25 software to calculate the half inhibitory concentration (IC50) of each test sample to inhibit NO release 50 ).

[0060] 3) Experimental results

[0061] According to the test results of MTT method and Griess method, the effects of ursolic acid and compounds Ⅰ-Ⅲ of the present invention on NO release of BV-2 cells induced by LPS were calculated. The results are shown in Table 3.

[0062] Table 3. Results of the test samples inhibiting LPS-induced NO release in BV-2 cells

[0063] Compound <![CDATA[IC 50 (μM)]]> Cell viability (%) L-NMMA 25.15±1.32 101.33±2.61 Arbutin 15.11±1.10 92.90±1.03 Compound Ⅰ 16.23±1.43 89.49±1.02 Compound II 8.84±1.03 97.45±1.10 Compound III 4.94±1.92 104.22±2.07

[0064] The results showed that compounds I-III of the present invention had no obvious cell inhibitory effect on BV-2, and at the same time could significantly reduce the release level of the inflammatory factor NO in BV-2 cells induced by LPS, and had good anti-neuroinflammatory activity. The anti-neuroinflammatory activity was also significantly better than the positive control L-NMMA, and could be used as the active ingredient of anti-neuroinflammatory drugs.

[0065] Example 4: Effects of the present invention's compound arbutin and compounds I-III on the learning and memory abilities of AD mouse models

[0066] 1) Establishment of AD mouse model

[0067] SPF male C57BL / 6 mice weighing 22-25 g were randomly divided into 6 groups, namely, blank control group, model group (D-gal (150 mg / kg) + NaNO2 (70 mg / kg) + Al Cl3 (40 mg / kg)), ursolic acid group (10 mg / kg), compound I group (2 mg / kg), compound II group (2 mg / kg) and compound III group (2 mg / kg). All drug powders were dispersed in 0.05% sodium carboxymethyl cellulose (CMC-Na). Except for the blank group, mice in other groups were subcutaneously injected with D-gal and NaNO2 and orally gavaged with Al Cl3 for 8 consecutive weeks to simulate the aging process (the normal group was injected with the same amount of 0.05% CMC-Na). After 4 weeks of modeling, all mice were gavaged with ursolic acid and compounds I-III at a dose of 10 or 2 mg / kg per day for 4 consecutive weeks.

[0068] 2) Experimental methods

[0069] The water maze laboratory is an experiment in which experimental animals are forced to swim and find a platform hidden in the water. The experimental animals need to remember the spatial position and direction to locate the position of the platform. The learning and memory ability of the experimental animals is evaluated by testing the time to find the platform. The present invention uses a circular pool with a diameter of 1 meter and a water temperature of 20°C. A platform with a diameter of 8 cm and a height of 0.9 cm below the water surface is placed in the pool. The model mice are trained in the pool for 4 days before the experiment. The mice are placed in the water with their heads facing the pool wall, and the positions are randomly selected in the four directions of east, west, south and north. The time it takes for the animal to find the platform within 60 seconds is recorded. If it exceeds 60 seconds, the animal is guided to the platform and stays for 10 seconds. Each animal is trained 5 times a day, with an interval of 30 minutes between each training. After the last training, the platform is removed, the experimental animal is placed in the pool, and the number and time of entering and staying in the quadrant where the platform was originally placed within 120 seconds are recorded. Four repetitions are set for each test group.

[0070] (3) Experimental results

[0071] Compared with the control group, the model group mice spent significantly less time in the platform quadrant, while the ursolic acid group and compound I–III group spent significantly more time in the platform quadrant. Figure 1 The results show that the ursolic acid and compounds I-III of the present invention can significantly improve the learning and memory ability of mice and can be used as active ingredients of drugs for treating nervous system diseases.

[0072] Example 5: Effects of the compounds arbutin and compounds I-III of the present invention on the learning and memory abilities of AD mouse models

[0073] 1) Experimental Materials

[0074] Instruments and reagents: CO2 incubator (Jouan I GO150); fluorescence inverted microscope (Olympus IX51); MTT cell proliferation and cytotoxicity detection kit (Biyuntian Biotechnology Research Institute), RPMI 1640 culture medium (Gibco lBRL), RNase A, fetal bovine serum, dimethyl sulfoxide (DMSO), trypsin (Shanghai Bioengineering Co., Ltd.).

[0075] The tumor cell lines used for the test: He la cells (human cervical cancer cells), K562 cells (human leukemia cells), K562 / ADR cells (human leukemia resistant cells), SH-SY5Y cells (human neuroblastoma cells), Du-145 (human prostate cancer cells), HePG2 cells (human liver cancer cells), MCF-7 cells (human breast cancer cells), CT26 cells (colon cancer cells), were purchased from the Institute of Oncology, Chinese Academy of Medical Sciences.

[0076] Test samples: arbutin and the compounds of formula I to formula VI synthesized in Example 1 and Example 2, with a purity of more than 95%; at the same time, cisplatin was selected as a positive control drug, and each compound was dissolved in DMSO and then diluted.

[0077] 2) Experimental methods

[0078] The MTT method was used to determine the half inhibition rate IC of each test compound on tumor cell lines. 50 Value: Take tumor cells in the logarithmic growth phase and adjust the cell concentration to 5×10 5 / mL, inoculated in a 96-well culture plate, 100 μL of cell suspension was added to each well of the drug-treated group and the cell control group, and 3 replicates were set up for each group. Only RPM I 1640 complete culture medium was added to the blank control group, 100 μL per well, and 3 replicates were set up. After the 96-well culture plate was placed in a 37°C, 5% CO2 incubator for 24 hours, different concentrations of the test samples were added to make the final concentration 0.1-100 μM, and the culture was continued for 72 hours. The absorbance (A) value at 570 nm was measured on a microplate reader according to the MTT method, and the inhibition rate was calculated [inhibition rate = (1-experimental group A value / control group A value) × 100%]. The experiment was repeated 3 times. SPSS11.5 software was used to make a regression equation to calculate the half-maximal inhibitory concentration (IC) of each test sample on tumor cells for 72 hours. 50 ).

[0079] 3) Experimental results

[0080] According to the MTT test results, calculate the IC of the test sample for the above cells 50 The results are shown in Table 2.

[0081] Table 2. In vitro cytotoxic activity screening results of test samples

[0082]

[0083] The results show that the compounds of formula I to formula III of the present invention have good anti-tumor activity and can be used as active ingredients of anti-tumor drugs. At the same time, the compounds of formula I to formula III of the present invention can effectively kill human leukemia resistant cells.

Claims

1. An ursodiol polyhydroxy derivative represented by any of the following structural formulas:

2. A method for preparing the polyhydroxy derivative of ursodiol according to claim 1, characterized in that: The preparation method comprises the following steps: 1) fermenting and culturing a microorganism, adding ursolic alcohol, performing transformation culture, removing mycelium, and obtaining a fermentation liquid, wherein the microorganism is Actinomucorelegans CGMCC3.3393; 2) extracting the fermentation broth with an organic solvent, and evaporating the extract to obtain a crude conversion extract; 3) purifying the crude conversion extract by reverse phase silica gel column chromatography, wherein the reverse phase silica gel column chromatography purification adopts a methanol-water two-phase system gradient elution, and collecting and merging the components; 4) Purifying the combined components obtained in step 3) by reverse phase high performance liquid chromatography to obtain the ursodiol polyhydroxy derivative.

3. Use of ursolic acid or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating a nervous system disease, wherein the structural formula of the ursolic acid is as follows:

4. Use of the ursodiol polyhydroxy derivative or a pharmaceutically acceptable salt thereof according to claim 1 in the preparation of a medicament for treating nervous system diseases.

5. The use according to claim 3 or 4, characterized in that: The drug for treating nervous system diseases is a drug for repairing nerve oxidative stress damage.

6. The use according to claim 3 or 4, characterized in that: The drug for treating nervous system diseases is a drug for resisting neuroinflammation.

7. The use according to claim 3 or 4, characterized in that: The drug for treating nervous system diseases is a drug for treating Alzheimer's disease.

8. Use of the ursodiol polyhydroxy derivatives according to claim 1 in the preparation of anti-tumor drugs, wherein the tumor comprises one of cervical cancer, leukemia, neuroblastoma, prostate cancer, liver cancer, breast cancer and colon cancer.

9. Use of the ursodiol polyhydroxy derivatives according to claim 1 in the preparation of a drug for killing leukemia drug-resistant cells.

10. A pharmaceutical composition comprising the ursool polyhydroxy derivative or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable excipient.

Citation Information

Patent Citations

  • Application of ursolic acid derivative in preparation of medicine for treating nervous system diseases

    CN113101293A

  • Application of ursolic acid derivatives in preparation of antitumor drugs

    CN113134006A

  • Application of ursane triterpenes in preparation of medicines for treating nervous system diseases

    CN116602971A

  • Urbutic derivative, microbial conversion preparation method and application

    CN116693593A